One of the biotechs funded by the Norwegian Coalition of Epidemic Preparedness Innovations (CEPI) to create a Covid-19 vaccine, Moderna has announced its hope that vaccine candidate, mRNA-1273, could be available for emergency use by autumn this year.
This announcement was made in a US securities and exchange commission (SEC) filing published on Moderna’s website. It stated that the company’s CEO Stèphane Bancel had informed Goldman Sachs representatives that although the timeline for a commercially available vaccine was still 12 to 18 months, “it is possible that under emergency use, a vaccine could be available to some people, possibly including healthcare professionals, in the fall of 2020.”
It seems the chances of this happening depends on the efficacy and safety results of Moderna’s about-to-be initiated Phase I trial for mRNA-1273. The company is being supported in this trial by the National Institute of Allergy and Infectious Diseases (NIAID).
